Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. (Q42985117)

12 November 2017

title

Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. (English)

1 reference

12 November 2017

author

Antonio Rivero-Juarez

1 reference

12 November 2017

1 reference

12 November 2017

1 reference

12 November 2017

1 reference

12 November 2017

1 reference

12 November 2017

J A Mira

1 reference

12 November 2017

A Camacho

1 reference

12 November 2017

I Perez-Camacho

1 reference

12 November 2017

J Torre-Cisneros

1 reference

12 November 2017

A Rivero

1 reference

12 November 2017

language of work or name

1 reference

14 October 2012

1 reference

12 November 2017

1 reference

12 November 2017

1 reference

12 November 2017

1 reference

12 November 2017

page(s)

21-26

1 reference

Hepatitis C virus infection

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Viral hepatitis and HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Identifying HCV genotype 1 patients at risk of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-012-0352-4

Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23065463

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S15010-012-0352-4

1 reference

12 November 2017

1 reference